LOADING...
Budget 2026-27: India to have 5 medical tourism hubs soon
The 'Biopharma Shakti programme' will have an allocation of ₹10,000 crore with private sector collaboration

Budget 2026-27: India to have 5 medical tourism hubs soon

Feb 01, 2026
12:54 pm

What's the story

In the Union Budget 2026-27, Finance Minister Nirmala Sitharaman has announced plans to set up five medical tourism hubs and launch a "Biopharma Shakti programme" with an allocation of ₹10,000 crore over five years. The initiative aims to make India a global leader in medical tourism services by establishing integrated healthcare complexes with private sector collaboration.

Hub details

Integrated healthcare complexes

The proposed medical tourism hubs will be multi-faceted healthcare complexes, combining medical, educational, and research facilities. They will include AYUSH centers, facilitation centers for medical value tourism, and infrastructure for diagnostics, post-care services, and rehabilitation. Sitharaman emphasized that these hubs would create a wide range of employment opportunities for health professionals such as doctors and allied health professionals (ALPs).

Expansion plans

Biopharma Shakti program

Along with the medical tourism hubs, Sitharaman also proposed to set up three new All India Institute of Ayurveda. The Biopharma Shakti program will create a biopharma-focused network with three new National Institutes of Pharmaceutical Education and Research (NIPERS) and upgrade seven existing ones. It will also establish a network of 1,000 accredited clinical trial sites in India.

Advertisement

Regulatory enhancements

Strengthening CDSCO for global standards

The Finance Minister also proposed strengthening the Central Drug Standard Control Organisation (CDSCO) to meet global standards and approval timeframes. This will be done through a dedicated scientific review cadre and specialists. The move is aimed at expediting drug approvals while maintaining high safety and efficacy standards, further bolstering India's position in the global biopharmaceutical industry.

Advertisement